Dr Walter Rodney Nagumo BSc. MSc. PhD.

Dr Walter Rodney Nagumo

Institute of Applied Health Research
Quality Assurance Manager

Contact details

Birmingham Clinical Trials Unit (BCTU)
University of Birmingham
B15 2TT

Walter-Rodney Nagumo joined Birmingham Clinical Trials Unit (BCTU) in January 2023 as Quality Assurance Manager.

He is responsible for ensuring best practices within the unit, identifying risks and mitigation strategies, enhancing local Standard Operating Procedures, interpreting regulatory and audit requirements and providing local guidance, training and support for clinical researchers and trial teams in BCTU.


  • PhD in Health Services Research-University of Sheffield, 2020
  • MSc. Clinical Trials, University of Ghana, 2013
  • BSc. Applied Biology, University for Development Studies, Ghana, 2009
  • Associate Fellow Advance HE, UK, 2019


Walter-Rodney Nagumo has educational backgrounds in Applied Biology (BSc.) and Clinical Trials (MSc.). His PhD was on pharmacovigilance and adverse drug reaction reporting practices among healthcare professionals. His research interests are therefore focused on pharmacovigilance, patient safety and safety reporting.  He previously worked at the University of Oxford’s Vaccines Group (OVG); Paediatrics Department, where he was a Quality Assurance Manager. At OVG he was responsible for the maintenance of the Quality Management System, supporting study teams in risk assessment coordination, review of regulatory documentation for study set up and closeout, QC of study specific training packages/documentation, non-clinical review of SAEs, coordinating study plan documentation, non-compliance management, study monitoring and auditing. He also worked briefly for a healthcare consultancy as a systematic review researcher.


Research interests

  • Pharmacovigilance
  • Patient safety
  • Mental health
  • Global Health
  • Health services research 

Other activities

  1. International Society for Pharmacovigilance (ISoP); Project Manager UKIRL Chapter

2. The International Society for Pharmacoepidemiology (ISPE)

3. Advance HE